Introduction
============

The mortality rate of epithelial ovarian cancer (EOC) ranks the first in female malignant tumors because of its hidden location, complicated pathogenesis, lack of early diagnosis and poor therapeutic effect ([@b1-ol-0-0-11213]). With the development of molecular biology, early screening indicators and biotherapeutic targets can be obtained by exploring the molecular mechanism of ovarian cancer development, which is of great significance for clinical diagnosis and treatment. WW domain-containing oxidoreductase (WWOX) gene is a potential tumor suppressor gene isolated and identified by Płuciennik *et al* ([@b2-ol-0-0-11213]) using shotgun gene sequencing technology. Many experimental studies have shown that WWOX expression deletion is closely related to the occurrence and development of a variety of cancers, including ovarian cancer ([@b3-ol-0-0-11213]). In this study, immunohistochemistry was used to detect the expression levels of WWOX, Elf5, Snail1 and EMT-related proteins in ovarian cancer tissues and to analyze their relationship with clinicopathological features. Correlation between WWOX and Elf5 expression levels and patient prognosis was further analyzed to explore the link between the tumor suppressor gene WWOX and the invasion and metastasis of ovarian cancer and the prognosis of patients from a clinical perspective.

Materials and methods
=====================

### Sources of information

In total 300 EOC paraffin embedding specimens of cancer tissue and corresponding normal ovarian tissues adjacent to each tumor (both normal tissues 2 cm away from the tumor edge, confirmed by pathology) were collected from 2010 to 2013, in the Gynaecology Department of Xuzhou No. 1 People\'s Hospital and Xuzhou Maternal and Child Health Care Hospital. Both hospitals are affiliated to Xuzhou Medical University. The surgical procedures were: tumor cytoreductive surgery (full uterus and double attachment + selective pelvic and abdominal aortic lymph node removal + omentectomy + appendectomy). Exclusion criteria: Patients with other systemic malignancies, metastatic cancers (including primary double cancer) from other organs of the reproductive system, or those who accepted chemotherapy, radiotherapy, or endocrine therapy as first treatment. All cases were complete with clinical, pathological and follow-up data. The selected patients were followed up until the patient died or January 2018. The follow-up period was 6--96 months. The enrolled patients were aged 17--74 years, with a median age of 53 years, 146 cases were ≥53 years, and 154 cases \<53 years. FIGO criteria: 143 cases of early stage (FIGO I + II stage), 157 cases of advanced stage (FIGO III + IV stage). The degree of differentiation: high differentiation + moderate differentiation (G1 + G2): 124 cases, poor differentiation (G3): 176 cases; pathological type: 168 cases of serous ovarian cancer, 63 cases of mucinous ovarian cancer, 54 cases of endometrial cancer, 15 cases of clear cell carcinoma; lymph node metastasis: 186 cases with metastasis, 114 cases without metastasis. In the same time period, the corresponding 300 adjacent normal tissues were selected as the control group. The study was approved by the Ethics Committee of Xuzhou No. 1 People\'s Hospital Affiliated to Xuzhou Medical University and Xuzhou Maternal and Child Health Care Hospital Affiliated to Xuzhou Medical University (Xuzhou, China). Informed consents were obtained from patients and their families.

### Reagent

Rabbit anti-human WWOX polyclonal antibody, rabbit anti-human Snail1 polyclonal antibody, rabbit anti-human E-cadherin polyclonal antibody, rabbit anti-human N-cadherin polyclonal antibody and rabbit anti-human vimentin polyclonal antibody were purchased from Wuhan Proteintech Biotechnology Co., Ltd., rabbit anti-human Elf5 polyclonal antibody was purchased from Beijing Bioss Biotechnology Co., Ltd., Hypersensitive Rabbit Two-Step Detection Kit (PV-9001) and DAB Colorimetric Kit were purchased from Beijing Zsjq Biotechnology Co., Ltd.

### Experimental methods

According to the grouping, all collected tissue samples were fixed with 4% neutral methanol, embedded in paraffin, and serially sectioned at 4 µm. The sections were dried and immersed in xylene for dewaxing and underwent dehydration of gradient ethanol. After citrate high-pressure antigen retrieval, the specimen was incubated in 3% hydrogen peroxide for 10 min at room temperature to block endogenous peroxidase. Six kinds of antibody dilutions (1:100) were added dropwise, incubated at 4°C overnight, and rewarmed at room temperature for 1 h, then added to the hypersensitive rabbit two-step test kit, incubated at 37°C for 20 min, and developed with DAB. After counterstaining, conventional dehydration, and neutral gum seals, the staining results were observed under a microscope.

### Determination of results

Independent double-blind readings were performed by two experienced pathologists to determine immunohistochemical staining results. All marker expression results were scored by the second scoring method based on the intensity of staining and the percentage of positive cells. Coloring intensity: colorless: 0 point; light yellow: 1 point; yellow: 2 points; brown yellow: 3 points. Percentage of positive cells: 10 high power fields (×400 times) were randomly selected from each sample, 100 cells were observed in each high power field, and the percentage of positive cells in each high power field was counted: \<5%: 0 point; 5--25%: 1 point; 26--50%: 2 points; 51--75%: 3 points; \>75%: 4 points, the median value was selected. The score of the staining intensity was added to the score of the percentage of positive cells, ≤3 was negative, and ≥4 was positive.

### Statistical analysis

Data analysis was performed using SPSS20.0 statistical software. The relationship between the expression of WWOX, Elf5, Snail1, E-cadherin, N-cadherin and vimentin in epithelial ovarian cancer tissues and corresponding adjacent tissues and the expression of various factors and clinicopathological parameters was detected by χ^2^ test; the relationship between WWOX and Elf5, WWOX, Snail1 and EMT marker factors and the positive expression between Elf5, Snail1 and EMT marker factors was determined by McNemar test; the relationship between WWOX and Elf5 and survival prognosis was examined by Kaplan-Meier survival analysis, and Cox multivariate regression model was used to analyze the factors affecting prognosis. P\<0.05 was considered statistically significant.

Results
=======

### Expression of WWOX, Elf5, Snail1 and EMT-related proteins in EOC tissues and adjacent normal tissues

WWOX was expressed in cytoplasm, Elf5 was expressed in the nucleus, Snail1 was expressed in the nucleus and cytoplasm, E-cadherin was expressed in the cell membrane, N-cadherin was expressed in the cell membrane and cytoplasm, and vimentin was expressed in the cytoplasm as brownish yellow particles ([Fig. 1](#f1-ol-0-0-11213){ref-type="fig"}). The expression of WWOX, Elf5, Snail1, E-cadherin, N-cadherin and vimentin were different in ovarian cancer and adjacent normal tissues, and the difference was statistically significant (P\<0.05). That is, WWOX, Elf5 and E-cadherin expression was low in ovarian cancer and highly expressed in adjacent tissues; Snail1, N-cadherin and vimentin were highly expressed in ovarian cancer and had low expression in adjacent tissues ([Table I](#tI-ol-0-0-11213){ref-type="table"}).

### Relationship between the expressions of WWOX, Elf5, Snail1 and EMT related proteins and clinicopathological parameters

Expression of WWOX, Elf5, Snail1 and EMT-related proteins in epithelial ovarian cancer were correlated with clinical stage, pathological grade and lymph node metastasis (P\<0.05), but not related to age and pathological type (P\>0.05). The later the clinical stage of EOC patients, the higher the pathological grade and the greater the lymph node metastasis and the lower the positive expression rate of WWOX, Elf5 and E-cadherin protein. The difference was statistically significant (P\<0.05) ([Tables II](#tII-ol-0-0-11213){ref-type="table"}--[VII](#tVII-ol-0-0-11213){ref-type="table"}).

### Correlation of WWOX, Elf5, Snail1 and EMT-related protein expression in EOC tissues

The expression levels of WWOX, Elf5, Snail1 and EMT markers in tissue sections of 300 patients with epithelial ovarian cancer were compared. The relationship between WWOX and Elf5 expression, the relationship between WWOX and Snail1 and EMT marker molecules, the relationship between Elf5 and Snail1 and EMT marker molecule expression were observed. The McNemar test was used to analyze the above relationships: The expression of WWOX and Elf5 was consistent (P\>0.05); the expression of WWOX was significantly different from those of Snail1, N-cadherin and vimentin (P\<0.05), and the expressions of WWOX and E-cadherin had consistency (P\>0.05); the expression of Elf5 was significantly different from those of Snail1, N-cadherin and vimentin (P\<0.05), and the expression of Elf5 and E-cadherin was consistent (P\>0.05), and the difference was statistically significant. The results suggest that the deletion of WWOX and Elf5 in epithelial ovarian cancer may promote the occurrence of Snail1-mediated EMT, which leads to the occurrence and development of epithelial ovarian cancer ([Tables VIII](#tVIII-ol-0-0-11213){ref-type="table"}--[IX](#tIX-ol-0-0-11213){ref-type="table"}).

### Survival analysis

The average 5-year survival rate of this group of patients was 22.3%. Forty-four patients were lost to follow-up. Kaplan-Meier survival analysis showed that patients with positive expression of WWOX and Elf5 had higher 5-year survival rate than patients with negative expression. The 5-year survival rates in WWOX protein positive group and WWOX protein negative group were 42.5 and 15.5%, respectively, and the difference was statistically significant (P\<0.05; [Fig. 2](#f2-ol-0-0-11213){ref-type="fig"}). The 5-year survival rates in Elf5 protein positive group and Elf5 protein negative group were 46.3 and 9.9%. The difference was statistically significant (P\<0.05; [Fig. 3](#f3-ol-0-0-11213){ref-type="fig"}). The statistical results showed that the prognosis of patients with positive WWOX expression was better than that of negative patients. The prognosis of patients with positive expression of Elf5 was better than that of negative patients, suggesting that WWOX and Elf5 were protective factors for epithelial ovarian cancer and can be used as indicators to judge the prognosis of patients.

### Cox multivariate regression analysis

The age of EOC patients (divided into aged ≥53 years group and \<53 years group), pathological type (serous cancer group, mucinous cancer group, endometrial cancer group, clear cell cancer group), FIGO stage (divided into I + II group and II + IV group), pathological grade (G1 + G2 group and G3 group), lymph node metastasis (divided into metastasis group and non-metastasis group), WWOX expression (divided into positive group and negative group), Elf5 expression (divided into positive and negative groups) and other factors were introduced into the Cox multivariate model. The results showed that WWOX, Elf5, FIGO stage, pathological grade and lymph node metastasis were independent factors affecting the prognosis of EOC patients ([Table X](#tX-ol-0-0-11213){ref-type="table"}).

Discussion
==========

Ovarian cancer is one of the three major malignant tumors in the female reproductive system. Most of the cases are advanced when observed, and the current clinical and other treatments cannot significantly improve the prognosis of patients with ovarian cancer, so the mortality rate of ovarian cancer remains high ([@b4-ol-0-0-11213]). Although molecular targeted therapy has achieved certain therapeutic effects, there is no systematic theoretical explanation for the pathogenesis of ovarian cancer. Therefore, an in-depth study of the mechanism of ovarian cancer is conducive to providing more effective treatment methods ([@b5-ol-0-0-11213]). The WWOX gene is a newly discovered tumor suppressor gene. Studies have shown that WWOX can interact with different proteins (such as p73, Ap2, ErbB4 and c-Jun) and can also be involved in many signal transduction pathways, such as the death domain of tumor necrosis factor receptor (TRADD) and tumor necrosis factor receptor-associated factor 2 (TRAF2) mediated apoptotic pathway, thereby inhibiting tumor proliferation and promoting tumor cell apoptosis ([@b6-ol-0-0-11213],[@b7-ol-0-0-11213]). Elf5 is located in the 13--15 region of the short arm of human chromosome 11, which is prone to loss of heterozygosity in cancer ([@b8-ol-0-0-11213],[@b9-ol-0-0-11213]). Lee and Ormandy ([@b10-ol-0-0-11213]) showed that the E3 domain of Elf5 is rich in proline and has protein binding function, while the WW1 domain in the WWOX protein binds to a proline-rich domain, and the WWOX protein interacts with the transcription factor Elf5 through this property. The transcription factor Elf5 is not only involved in cell development, differentiation and apoptosis, but also regulates cell proliferation and tumorigenesis ([@b11-ol-0-0-11213]). Yan *et al* ([@b12-ol-0-0-11213]) showed that WWOX mRNA expression in ovarian cancer tissues was lower than that in normal ovarian tissue. Yan *et al* ([@b11-ol-0-0-11213]) showed that the expression of Elf5 mRNA in ovarian cancer tissues was lower than that in normal ovarian tissues. In this study, the expression of WWOX and Elf5 in 300 ovarian cancer tissues and adjacent normal tissues were detected by immunohistochemical method. It was found that expression of WWOX and Elf5 was low in ovarian cancer tissues, and highly expressed in adjacent tissues (P\<0.05), indicating that the low expression of WWOX and Elf5 may be closely related to the occurrence of ovarian cancer.

EMT is a critical step in the development of ovarian cancer invasion, metastasis and drug resistance. It refers to the non-movable polar epithelial cells replaced by movable and migrating interstitial cells under certain special physiological or pathological conditions, and epithelial cells have the phenotype of interstitial cells ([@b13-ol-0-0-11213]). The occurrence of EMT is regulated by a variety of growth factors and multiple signal transduction pathways. In recent years, the Snail1/E-cadherin signaling pathway has been proven by several studies ([@b14-ol-0-0-11213],[@b15-ol-0-0-11213]). Increased expression of the zinc finger transcription factor Snail1 in ovarian cancer can be combined with the E-box promoter on E-cadherin to inhibit the expression of E-cadherin, preventing cells from adhering together, thereby inducing ovarian cancer and causing invasiveness ([@b16-ol-0-0-11213]). Moreover, EMT mesenchymal markers N-cadherin and vimentin showed increased expression. N-cadherin and vimentin can loosen the tumor cells, resulting in migration and spread ([@b17-ol-0-0-11213],[@b18-ol-0-0-11213]). The results of this study showed that E-cadherin expression was low in EOC tissues and highly expressed in adjacent tissues; Snail1, N-cadherin and vimentin were highly expressed in EOC tissues and the expression was low in adjacent tissues, which was consistent with related studies and the molecular biological characteristics of the EMT process of ovarian cancer.

In this study, it was also concluded that the lower the expression of WWOX and Elf5, the more serious the EMT phenomenon, resulting in invasion and metastasis of ovarian cancer. The higher the pathological grade, the later the surgical pathological stage, the more prone to lymph node metastasis, and the worse the prognosis of patients. In multivariate analysis, the independent influencing factors are relative to the dependent variable (i.e., survival time), not to the independent variable. Given interrelationship between the independent variables, the independent variables (FIGO stage, pathological grade, lymph node metastasis, WWOX and Elf5) were included in a multi-factor regression model.

The results of this study showed that the expression of WWOX and Elf5 in epithelial ovarian cancer tissues was consistent, and the expression may be positively correlated, however, this needs to be confirmed in a future study.

In summary, WWOX acts as a tumor suppressor gene, and the transcription factor Elf5 also has the function as a tumor suppressor gene. The loss of expression of both may promote the EMT phenomenon of ovarian cancer and further promotes the invasion and metastasis of ovarian cancer. WWOX is also expected to be an indicator of early screening for ovarian cancer and a new target for biotherapy. However, the molecular biological mechanism of ovarian cancer is a multi-step, multi-gene regulation process. The specific mechanism as to how the tumor suppressor gene WWOX inhibits EMT in ovarian cancer by Elf5/Snail1 remains to be further studied.
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![WWOX, Elf5, Snail1 and EMT-related protein expression in EOC tissues and adjacent normal tissues. (A) Low expression of WWOX in EOC (×400). (B) High expression of WWOX in adjacent tissues (×400). (C) Low expression of Elf5 in EOC (×400). (D) High expression of Elf5 in adjacent tissues (×400). (E) High expression of Snail1 in EOC (×400). (F) Low expression of Snail1 in adjacent tissues (×400). (G) Low expression of E-cadherin in EOC (×400). (H) High expression of E-cadherin in adjacent tissues (×400). (I) High expression of N-cadherin in EOC (×400). (J) Low expression of N-cadherin in adjacent tissues (×400). (K) High expression of vimentin in EOC (×400). (L) Low expression of vimentin in adjacent tissues (×400). WWOX, WW domain-containing oxidoreductase; EMT, epithelial-mesenchymal transition; EOC, epithelial ovarian cancer.](ol-19-02-1281-g00){#f1-ol-0-0-11213}

![The 5-year survival rates of WWOX protein positive and negative groups. Lost cases are patients who cannot be reached, and those whose died of an accident (such as a car accident) or other illness (such as cardiovascular and cerebrovascular). Positive-lost, the lost cases with positive factor expression. Negative-lost, the lost cases with negative factor expression. WWOX, WW domain-containing oxidoreductase.](ol-19-02-1281-g01){#f2-ol-0-0-11213}

![The 5-year survival rates of Elf5 protein positive and negative groups. Lost cases are patients who cannot be reached, and those whose died of an accident (such as a car accident) or other illness (such as cardiovascular and cerebrovascular). Positive-lost, the lost cases with positive factor expression. Negative-lost, the lost cases with negative factor expression.](ol-19-02-1281-g02){#f3-ol-0-0-11213}

###### 

Expression of different proteins in ovarian cancer and adjacent normal tissues.

  Protein      Group                   Total number of cases (n)   Positive (case)   Negative (case)   Positive rate (%)
  ------------ ----------------------- --------------------------- ----------------- ----------------- -------------------
  WWOX         Ovarian cancer group    300                         113               187               37.7
               Adjacent tissue group   300                         264               36                88.0
  Elf5         Ovarian cancer group    300                         108               192               36.0
               Adjacent tissue group   300                         263               37                87.7
  Snail1       Ovarian cancer group    300                         199               101               66.3
               Adjacent tissue group   300                         27                273               9.0
  E-cadherin   Ovarian cancer group    300                         91                209               30.3
               Adjacent tissue group   300                         240               60                80.0
  N-cadherin   Ovarian cancer group    300                         154               146               51.3
               Adjacent tissue group   300                         42                258               14.0
  Vimentin     Ovarian cancer group    300                         196               104               65.3
               Adjacent tissue group   300                         24                276               8.0

WWOX, WW domain-containing oxidoreductase.

###### 

Correlation between WWOX expression and clinicopathological parameters in epithelial ovarian cancer.

                                  WWOX expression                        
  ------------------------- ----- ----------------- ---- ------ -------- ---------
  Age (years)                                                            
    \<53                    154   95                59   38.3   0.056    0.813
    ≥53                     146   92                54   37.0            
  Pathological type                                                      
    Serous carcinoma        168   104               64   38.1   0.194    0.978
    Mucinous carcinoma      63    39                24   38.1            
    Endometrial carcinoma   54    35                19   35.2            
    Clear cell carcinoma    15    9                 6    40.0            
  FIGO staging                                                           
    I--II                   143   75                68   47.6   11.374   0.001
    III--IV                 157   112               45   28.7            
  Pathological staging                                                   
    G1+G2                   124   59                65   52.4   19.593   \<0.001
    G3                      176   128               48   27.3            
  Lymph node metastasis                                                  
    Yes                     186   134               52   28.0   19.654   \<0.001
    No                      114   53                61   53.5            

WWOX, WW domain-containing oxidoreductase.

###### 

Correlation between Elf5 expression and clinicopathological parameters in epithelial ovarian cancer.

                                  Elf5 expression                          
  ------------------------- ----- ----------------- ---- -------- -------- ---------
  Age (years)                                                              
    \<53                    154   99                55     35.7   0.011    0.916
    ≥53                     146   93                53     36.3            
  Pathological type                                                        
    Serous carcinoma        168   106               62     36.9   0.153    0.985
    Mucinous carcinoma      63    41                22     34.9            
    Endometrial carcinoma   54    35                19     35.2            
    Clear cell carcinoma    15    10                5      33.3            
  FIGO staging                                                             
    I--II                   143   78                65     45.6   10.601   0.001
    III--IV                 157   114               43     27.4            
  Pathological staging                                                     
    G1+G2                   124   62                62     50.0   17.981   \<0.001
    G3                      176   130               46     26.1            
  Lymph node metastasis                                                    
    Yes                     186   137               49     26.3   19.808   \<0.001
    No                      114   55                59     51.8            

###### 

Correlation between Snail1 expression and clinicopathological parameters in epithelial ovarian cancer.

                                  Snail1 expression                         
  ------------------------- ----- ------------------- ----- ------ -------- ---------
  Age (years)                                                               
    \<53                    154   51                  103   66.9   0.043    0.836
    ≥53                     146   50                  96    65.8            
  Pathological type                                                         
    Serous carcinoma        168   55                  113   67.2   0.166    0.983
    Mucinous carcinoma      63    22                  41    65.1            
    Endometrial carcinoma   54    19                  35    64.8            
    Clear cell carcinoma    15    5                   10    66.7            
  FIGO staging                                                              
    I--II                   143   64                  79    55.2   15.044   \<0.001
    III--IV                 157   37                  120   76.4            
  Pathological staging                                                      
    G1+G2                   124   72                  52    41.9   56.338   \<0.001
    G3                      176   29                  147   83.5            
  Lymph node metastasis                                                     
    Yes                     186   32                  154   82.8   59.399   \<0.001
    No                      114   69                  45    39.5            

###### 

Correlation between E-cadherin expression and clinicopathological parameters in epithelial ovarian cancer.

                                  E-cadherin expression                        
  ------------------------- ----- ----------------------- ---- ------ -------- ---------
  Age (years)                                                                  
    \<53                    154   106                     48   31.2   0.105    0.746
    ≥53                     146   103                     43   29.5            
  Pathological type                                                            
    Serous carcinoma        168   116                     52   31.0   0.139    0.987
    Mucinous carcinoma      63    44                      19   30.2            
    Endometrial carcinoma   54    38                      16   29.6            
    Clear cell carcinoma    15    11                      4    26.7            
  FIGO staging                                                                 
    I--II                   143   63                      80   55.9   84.812   \<0.001
    III--IV                 157   146                     11   7.0             
  Pathological staging                                                         
    G1+G2                   124   50                      74   59.7   86.124   \<0.001
    G3                      176   159                     17   9.7             
  Lymph node metastasis                                                        
    Yes                     186   158                     28   15.1   54.076   \<0.001
    No                      114   51                      63   55.3            

###### 

Correlation between N-cadherin expression and clinicopathological parameters in epithelial ovarian cancer.

                                  N-cadherin expression                         
  ------------------------- ----- ----------------------- ----- ------ -------- ---------
  Age (years)                                                                   
    \<53                    154   74                      80    51.9   0.048    0.827
    ≥53                     146   72                      74    50.7            
  Pathological type                                                             
    Serous carcinoma        168   81                      87    51.8   0.211    0.976
    Mucinous carcinoma      63    30                      33    52.4            
    Endometrial carcinoma   54    27                      27    50.0            
    Clear cell carcinoma    15    8                       7     46.7            
  FIGO staging                                                                  
    I--II                   143   104                     39    27.3   63.320   \<0.001
    III--IV                 157   42                      115   73.2            
  Pathological staging                                                          
    G1+G2                   124   88                      36    29.0   42.078   \<0.001
    G3                      176   58                      118   67.0            
  Lymph node metastasis                                                         
    Yes                     186   63                      123   66.1   42.891   \<0.001
    No                      114   83                      31    27.2            

###### 

Correlation between vimentin expression and clinicopathological parameters in epithelial ovarian cancer.

                                  Vimentin expression                         
  ------------------------- ----- --------------------- ----- ------ -------- ---------
  Age (years)                                                                 
    \<53                    154   53                    101   65.6   0.009    0.925
    ≥53                     146   51                    95    65.1            
  Pathological type                                                           
    Serous carcinoma        168   56                    112   66.7   0.372    0.946
    Mucinous carcinoma      63    23                    40    63.5            
    Endometrial carcinoma   54    20                    34    63.0            
    Clear cell carcinoma    15    5                     10    66.7            
  FIGO staging                                                                
    I--II                   143   85                    58    40.6   74.046   \<0.001
    III--IV                 157   19                    138   87.9            
  Pathological staging                                                        
    G1+G2                   124   76                    48    38.7   66.148   \<0.001
    G3                      176   28                    148   84.1            
  Lymph node metastasis                                                       
    Yes                     186   38                    148   79.6   43.802   \<0.001
    No                      114   66                    48    42.1            

###### 

Correlation analysis between Elf5 with WWOX, E-cadherin, Snail1, N-cadherin and vimentin.

               Elf5                        
  ------------ ------ ----- ----- -------- ---------
  WWOX                                     
    Positive   61     52    113   0.253    0.688
    Negative   47     140   187            
    Total      108    192   300            
  E-cadherin                               
    Positive   60     31    91    3.658    0.071
    Negative   48     161   209            
    Total      108    192   300            
  Snail1                                   
    Positive   15     184   199   29.895   \<0.001
    Negative   93     8     101            
    Total      108    192   300            
  N-cadherin                               
    Positive   22     132   154   9.706    0.002
    Negative   86     60    146            
    Total      108    192   300            
  Vimentin                                 
    Positive   20     176   196   29.333   \<0.001
    Negative   88     16    104            
    Total      108    192   300            

WWOX, WW domain-containing oxidoreductase.

###### 

Correlation analysis between WWOX and Snail1, E-cadherin, N-cadherin and vimentin.

               WWOX                        
  ------------ ------ ----- ----- -------- ---------
  Snail1                                   
    Positive   21     178   199   27.393   \<0.001
    Negative   92     9     111            
    Total      113    187   300            
  E-cadherin                               
    Positive   41     50    91    3.967    0.057
    Negative   72     137   209            
    Total      113    187   300            
  N-cadherin                               
    Positive   23     131   154   7.606    0.007
    Negative   90     56    146            
    Total      113    187   300            
  Vimentin                                 
    Positive   25     171   196   26.598   \<0.001
    Negative   88     16    104            
    Total      113    187   300            

WWOX, WW domain-containing oxidoreductase.

###### 

Multivariate analysis of 300 patients with EOC.

  Variable                B        SE      Wald     df   P-value   Exp (B)   95% CI
  ----------------------- -------- ------- -------- ---- --------- --------- --------------
  FIGO staging            1.015    0.191   28.129   1    0.001     2.760     1.897--4.017
  Pathological grading    0.745    0.152   23.985   1    0.001     2.106     1.563--2.837
  Lymph node metastasis   0.455    0.190   5.726    1    0.017     1.576     1.086--2.288
  WWOX                    −0.661   0.145   20.806   1    0.001     0.516     0.389--0.686
  Elf5                    −1.399   0.161   75.121   1    0.001     0.247     0.180--0.339

WWOX, WW domain-containing oxidoreductase.
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